Return to Main MASCC Website

Speaker Guidelines

Speaker Resources

Thank you to all our Invited Speakers, Invited Panelists, Session Chairs, and Abstract Presenters (Oral Proffered Papers & e-posters).

If the information below does not answer your questions, please email events@mascc.org.
All presenting author changes must be received by April 17, 2024 sent to events@mascc.org.
For technical support or login issues with an e-poster submission, please email support@simul-europe.com.

Speaker Ready Room Hours

All Invited Speakers/Oral Proffered Paper Presenters/Session Chairs are asked to visit the Speaker Ready Room a minimum of TWO (2) hours before your session to submit your PowerPoint slide deck on a USB thumb drive
Note: This may mean that you need to submit your presentation the day BEFORE your presentation date.

Location: Room 2.1
Hours: To be confirmed

E-Poster Presentations

Presentation Date & Time: This will be shared closer to the Meeting Dates
Presentation Length: 3 minutes + 2 minutes Q&A
Presentation Media: Single-page PDF e-poster

All e-poster presenters will be notified by mid-late March 2024 of their acceptance by email. We will notify e-poster presenters of their e-poster session date, time, and e-poster stage number in late April. There will be six (6) e-poster stages in the Exhibition Hall. 

To prepare for your presentation at the 2024 Annual Meeting, please refer to the information below. Please expand the items below for more information.

  • Ensure that one (1) co-author is registered by the Early Bird Deadline. All abstracts must have one (1) co-author registered by the Early Bird Deadline to be included in the Scientific Program and published in the journal Supportive Care in Cancer. Typically, this is the Presenting Author.
  • Submit changes to the Presenting Author by the Early Bird Deadline to events@mascc.org.
  • Ensure that the Presenting Author is registered by Wednesday, June 5, 2024. ***An individual may be a presenting author on a maximum of two (2) abstracts.***
  • Prepare and submit your e-poster by Friday, June 7, 2024.
  • Please review the MASCC/AFSOS/ISOO 2024 Annual Meeting Terms of Service here

DEADLINE FOR E-POSTER SUBMISSION: June 5, 2024.
Presenting Authors will be sent an email in late April by our e-poster partners, SIMUL, with your login details to create and upload your e-poster presentation. Once you log into the platform, you will see a list of the e-posters we are expecting you to upload.

For technical questions or login issues, please contact support@simul-europe.com.

Size & Format:

  • One page only
  • File Format: .PDF
  • Orientation: Landscape (horizontal)
  • Format: 16:9
  • In inches: 18” height x 32” width
  • In cm: 45.72 cm height x 81.28 cm width
  • In pixels: 2000 px height x 1125 px width (minimum requirement)
  • DPI: 300 pixels/inch
  • Recommended Font Size: 16 pt
  • Maximum file size: 5 MB
  • Media: Images, graphs, and tables may be included in the e-poster
  • Video: You may include video with your e-poster (maximum of 1 video per e-poster, maximum file size with video is 40 MB). In order to embed video or audio in your .pdf, please use Adobe Acrobat Pro and only use mp4 files.

Additional Notes:

  • Presentations must be prepared in English.
  • All content must be evidence-based, or include an explanation why it is not:
  • Ensure that you note your references including: authors, titles, article title, year, volume, and page numbers in your materials.
    • Evidence must come from systematic reviews/meta-analyses of studies (randomized control trials (RCTs), cohort case control studies), or single, moderate-sized, well designed RCTs, or well-designed, consistent, controlled, non-randomized trials or large cohort studies.
    • Any lack of evidence for assertions or recommendations must be acknowledged.
    • If a single study is the focus or select studies are omitted, the rationale to support this decision must be included.
    • Graphs and charts or other evidence-related materials cannot be altered to highlight one treatment or product.
    • Both potential harms and benefits should be discussed; an efficient way to present these to clinicians is through number needed to treat (NNT) and number needed to harm (NNH), as well as through a presentation of absolute and relative risk reductions.
  • Refer to all medications by the generic name. If brand names must be used, the brand name should appear in parentheses after the generic name. Every drug mentioned should be referred to in a similar manner.
  • Hospital, institution, association, or charitable logos are permitted.
  • Pharmaceutical or corporate commercial logos are only permitted to disclose support of any kind provided by a commercial entity. 
  • Please be mindful of patient privacy rules when sharing any research data. All information shared must remain anonymous.
  • QR codes or website links may be used, however, they cannot link to promotional websites/documents.
  • You will find templates available on SIMUL’s platform. It is not mandatory that you use these.
  •  
  • E-poster presentations will be held in the Exhibition Hall.
  • You will have a designated e-poster stand number and scheduled time.
  • Please go to your assigned e-poster stand number a minimum of 15 minutes prior to your scheduled presentation time.
  • The e-poster chair will call on you to present your e-poster.
  • You will have three (3) minutes to make your presentation and two (2) minutes for questions.
  • You will stand next to your e-poster displayed on a monitor (no physical printouts required).
  • You will have a tablet linked to the e-poster displayed on the television, which you may “pinch and zoom” to various parts of your e-poster for the viewing delegates.
  • You will speak into a microphone, which will provide audio to headsets for the viewing delegates to hear you more clearly in the busy Exhibition Hall.
  • The Session Chair will facilitate questions from the audience. If English is not your first language and you need assistance, please bring a registered delegate to help with translation.
  • E-posters will be on display at the e-poster stations throughout the entire Annual Meeting. Delegates may view your e-poster at their leisure and will have the opportunity to email you with questions with a “contact author” button available on the e-poster tablets.

Oral Proffered Papers

Presentation Date & Time: Please refer to your abstract acceptance email for details.
Presentation Length: 10 minutes
Presentation Media: PowerPoint slides (Download the 2024 template here)

All oral proffered paper presenters will be notified by mid-late March 2024 of their acceptance notifications by email with your assigned session title, presentation date and time. 

To prepare for your presentation at the 2024 Annual Meeting, please refer to the information below. Please expand the items below for more information.

  • Ensure that one (1) co-author is registered by the Early Bird Deadline. All abstracts must have one (1) co-author registered by the Early Bird Deadline to be included in the Scientific Program and published in the journal Supportive Care in Cancer. Typically, this is the Presenting Author.
  • Submit changes to the Presenting Author by the Early Bird Deadline to events@mascc.org.
  • Ensure that the Presenting Author is registered by the Early Bird Deadline. ***An individual may be a presenting author on a maximum of two (2) abstracts.***
  • Ensure that the Presenting Author has emailed a short biography (1 paragraph) and photo headshot to events@mascc.org by the Early Bird Deadline. 
  • Prepare your PowerPoint slides for your presentation.
  • Please review the MASCC/AFSOS/ISOO 2024 Annual Meeting Terms of service here.
  • Download the 2024 Template Here – We encourage all presenters to use this template.
  • Please name your PPT file “[Your Full Name][Session Date][Session Start Time][any version control codes you like].pptx”.
  • Verbally share your Conflict(s) of Disclosure and include it immediately after your title slide.
  • Verbally share the Learning Objectives and include it after your Conflicts of Disclosure slide.
  • All content must be evidence-based, or include an explanation why it is not:
    • Ensure that you note your references including: authors, titles, article title, year, volume, and page numbers in your materials.
    • Evidence must come from systematic reviews/meta-analyses of studies (randomized control trials (RCTs), cohort case control studies), or single, moderate-sized, well designed RCTs, or well-designed, consistent, controlled, non-randomized trials or large cohort studies.
    • Any lack of evidence for assertions or recommendations must be acknowledged.
    • If a single study is the focus or select studies are omitted, the rationale to support this decision must be included.
    • Graphs and charts or other evidence-related materials cannot be altered to highlight one treatment or product.
    • Both potential harms and benefits should be discussed; an efficient way to present these to clinicians is through number needed to treat (NNT) and number needed to harm (NNH), as well as through a presentation of absolute and relative risk reductions.
  • Refer to all medications by the generic name. If brand names must be used, the brand name should appear in parentheses after the generic name. Every drug mentioned should be referred to in a similar manner.
  • Presentations must be prepared in English.
  • Hospital, institution, association, or charitable logos are permitted.
  • Pharmaceutical or corporate commercial logos are not permitted, however any conflict of disclosure must be declared immediately after your title slide.
  • QR codes or website links may be used, however, they cannot link to promotional websites/documents.
  • Please be mindful of patient privacy rules when sharing any research data. All information shared must remain anonymous.
  • Please use common fonts, such as Arial and Verdana.
  • Insert photos as .JPG files to ensure visibility in PowerPoint.
  • When you arrive at the meeting venue, please visit the Speaker Ready Room to submit your PowerPoint slides a minimum of two (2) hours before your session.
  • You must provide your presentation on a USB thumb drive to load onto the conference computers. The Speaker Ready Room in Room 2.1
  • Hours for the Speaker Ready Room will be posted closer to the meeting dates.
  • By submitting your presentation to the Speaker Ready Room, we will ensure your presentation is in the appropriate session room for projection.
  • Most parallel sessions include two (2) Invited Speakers. Oral proffered papers will be presented after the Invited Speakers. The Session Chair will introduce you and call you up when it is your turn to present.
  • There will be a TV screen facing you to display your slides (comfort monitor).
  • You will have a handheld remote to advance your slides.
  • There will be a speaker clock to help you keep time.
  • You will have ten (10) minutes for your presentation.
  • The session will end with a Q&A period.

Invited Speakers & Session Chairs

Presentation Date & Time: Please refer to your speaker invitation and session introductions for details.
Presentation Length: Please refer to your speaker invitation and session introduction for details. You may also consult the Scientific Program for details.
Presentation Media: PowerPoint slides (Download the 2024 template here)

To prepare for your presentation at the 2024 Annual Meeting, please refer to the information below. Please expand the items below for more information.

  • Download the 2024 Template Here – We encourage all presenters to use this template.
  • Please name your PPT file “[Your Full Name][Session Date][Session Start Time][any version control codes you like].pptx”.
  • Verbally share your Conflict(s) of Disclosure and include it after your title slide.
  • Verbally share the Learning Objectives and include it after your Conflicts of Disclosure slide.
  • All content must be evidence-based, or include an explanation why it is not:
    • Ensure that you note your references including: authors, titles, article title, year, volume, and page numbers in your materials.
    • Evidence must come from systematic reviews/meta-analyses of studies (randomized control trials (RCTs), cohort case control studies), or single, moderate-sized, well designed RCTs, or well-designed, consistent, controlled, non-randomized trials or large cohort studies.
    • Any lack of evidence for assertions or recommendations must be acknowledged.
    • If a single study is the focus or select studies are omitted, the rationale to support this decision must be included.
    • Graphs and charts or other evidence-related materials cannot be altered to highlight one treatment or product.
    • Both potential harms and benefits should be discussed; an efficient way to present these to clinicians is through number needed to treat (NNT) and number needed to harm (NNH), as well as through a presentation of absolute and relative risk reductions.
  • Refer to all medications by the generic name. If brand names must be used, the brand name should appear in parentheses after the generic name. Every drug mentioned should be referred to in a similar manner.
  • Presentations must be prepared in English.
  • Hospital, institution, association, or charitable logos are permitted.
  • Pharmaceutical or corporate commercial logos are not permitted, however any conflict of disclosure must be declared immediately after your title slide.
  • QR codes or website links may be used, however, they cannot link to promotional websites/documents.
  • Please be mindful of patient privacy rules when sharing any research data. All information shared must remain anonymous.
  • Please use common fonts, such as Arial and Verdana.
  • Insert photos as .JPG files to ensure visibility in PowerPoint.
  • When you arrive at the meeting venue, please visit the Speaker Ready Room to submit your PowerPoint slides a minimum of two (2) hours before your session.
  • You must provide your presentation on a USB thumb drive to load onto the conference computers. The Speaker Ready Room is located in Room 2.1.
  • Hours for the Speaker Ready Room will be posted closer to the meeting dates.
  • By submitting your presentation to the Speaker Ready Room, we will ensure your presentation is in the appropriate session room for projection.
  • Please be seated at the panelist desks at the front of the room, reserving the seat(s) closest to the podium for the Session Chair(s).
  • The Session Chair will introduce you and call you up when it is your turn to present.
  • There will be a TV screen facing you to display your slides (comfort monitor).
  • You will have a handheld remote to advance your slides.
  • There will be a speaker clock to help you keep time.
  • The session will end with a Q&A period.